Academic Journal
Study protocol on the role of intestinal microbiota in colorectal cancer treatment:a pathway to personalized medicine 2.0
| العنوان: | Study protocol on the role of intestinal microbiota in colorectal cancer treatment:a pathway to personalized medicine 2.0 |
|---|---|
| المؤلفون: | Aarnoutse, R., de Vos-Geelen, J. M. P. G. M., Penders, J., Boerma, E. G., Warmerdam, F. A. R. M., Goorts, B., Damink, S. W. M. Olde, Soons, Z., Rensen, S. S. M., Smidt, M. L. |
| المصدر: | Aarnoutse , R , de Vos-Geelen , J M P G M , Penders , J , Boerma , E G , Warmerdam , F A R M , Goorts , B , Damink , S W M O , Soons , Z , Rensen , S S M & Smidt , M L 2017 , ' Study protocol on the role of intestinal microbiota in colorectal cancer treatment : a pathway to personalized medicine 2.0 ' , International Journal of Colorectal Disease , vol. 32 , no. 7 , pp. 1077-1084 . https://doi.org/10.1007/s00384-017-2819-3 |
| سنة النشر: | 2017 |
| المجموعة: | Maastricht University Research Publications |
| مصطلحات موضوعية: | Intestinal microbiota, Colorectal cancer treatment, RANDOMIZED-TRIAL, CAPECITABINE, CARCINOGENESIS, FLUOROURACIL, CHEMOTHERAPY |
| الوصف: | Purpose Investigate in patients with metastatic and/or irresectable colorectal cancer treated with systemic treatment with capecitabine or TAS-102 whether: 1. Intestinal microbiota composition can act as a predictor for response. 2. Intestinal microbiota composition changes during systemic treatment and its relation to chemotoxicity. Background Gut microbiota and host determinants evolve in symbiotic and dependent relationships resulting in a personal ecosystem. In vitro studies showed prolonged and increased response to 5-fluorouracil, a fluoropyrimidine, in the presence of a favorable microbiota composition. Capecitabine and TAS-102 are both fluoropyrimidines used for systemic treatment in colorectal cancer patients. Methods An explorative prospective multicenter cohort study in the Maastricht University Medical Centre+ and Zuyderland Medical Centre will be performed in 66 patients. Before, during, and after three cycles of systemic treatment with capecitabine or TAS-102, fecal samples and questionnaires (concerning compliance and chemotoxicity) will be collected. The response will be measured by CT/ MRI using RECIST-criteria. Fecal microbiota composition will be analyzed with 16S rRNA next-generation sequencing. The absolute bacterial abundance will be assessed with quantitative polymerase chain reaction. Multivariate analysis will be used for statistical analysis. Conclusions We aim to detect a microbiota composition that predicts if patients with metastatic and/ or irresectable colorectal cancer will respond to systemic treatment and/ or experience zero to limited chemotoxicity. If we are able to identify a favorable microbiota composition, fecal microbiota transplantation might be the low-burden alternative to chemotherapy switch in the future. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | https://cris.maastrichtuniversity.nl/en/publications/4dfdc521-0d74-4b5f-90e7-6d44973fee8a |
| DOI: | 10.1007/s00384-017-2819-3 |
| الاتاحة: | https://cris.maastrichtuniversity.nl/en/publications/4dfdc521-0d74-4b5f-90e7-6d44973fee8a https://doi.org/10.1007/s00384-017-2819-3 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.E3F1F155 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s00384-017-2819-3 |
|---|